Oncologists focusing on the human prostate have found that RNY1, RNY3, RNY4, and RNY5 are downregulated in prostate adenocarcinoma versus normal tissue and benign prostate hyperplasia [32]. Here, RNY4 is linked to benign prostatic hyperplasia.